Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Debt / NOTE 1.000% 8/1
-
Number of holders
-
72
-
Total 13F principal, excl. options
-
658,912,150
-
Principal change
-
-4,060,700
-
Total reported value, excl. options
-
$616,721,993
-
Value change
-
-$3,988,874
-
Number of buys
-
31
-
Number of sells
-
-25
-
Price
-
$0.9309
Significant Holders of HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 as of Q4 2023
80 filings reported holding 40637HAF6 - HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 as of Q4 2023.
HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 has 72 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $658,912,150 of principal
.
Largest 10 bondholders include LINDEN ADVISORS LP ($99,826,000 of principal), Calamos Advisors LLC ($63,701,000 of principal), ADVENT CAPITAL MANAGEMENT /DE/ ($55,993,000 of principal), WOLVERINE ASSET MANAGEMENT LLC ($51,189,000 of principal), MACKAY SHIELDS LLC ($45,324,000 of principal), CITADEL ADVISORS LLC ($33,209,000 of principal), Magnetar Financial LLC ($21,200,000 of principal), Polar Asset Management Partners Inc. ($20,000,000 of principal), MILLENNIUM MANAGEMENT LLC ($15,500,000 of principal), and STATE STREET CORP ($15,300,000 of principal).
This table shows the top 72 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.